Michael Mader

Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results

Identification of a Small Interface between the Methyltransferase and RNA Polymerase of NS5 that is Essential for Zika Virus Replication

Emerging therapies for the treatment of hepatitis C

Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir

Definition and classification of cancer cachexia: an international consensus

Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations

Appraisal of current and experimental approaches to the treatment of cachexia

The FDA-approved drug sofosbuvir inhibits Zika virus infection

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy

The ProTide Prodrug Technology: From the Concept to the Clinic

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection

Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B

Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach

Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate

EASL Recommendations on Treatment of Hepatitis C 2018

Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential

Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial

Intravenous ghrelin for cancer-related anorexia/cachexia: A randomized, placebo-controlled, double-blind, double cross-over phase I/II study

1120 PSI-7977 400 MG QD SAFETY AND TOLERABILITY IN THE FIRST 450 PATIENTS TREATED FOR 12 WEEKS